Quantum Biopharma (QNTM) Convertible Debt (2024 - 2026)

Quantum Biopharma has disclosed Convertible Debt across 3 years of filings, most recently posting $485517.0 for Q1 2026.

• Convertible Debt for Q1 2026 came in at $485517.0, up 209.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $485517.0 (up 209.4% YoY), and the FY2025 annual result was $472497.0, up 210.62% from the prior year.
• Convertible Debt came in at $485517.0 for Q1 2026 at Quantum Biopharma, up from $472497.0 in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $485517.0 in Q1 2026 to a low of $152113.0 in Q4 2024.
• The 3-year median for Convertible Debt is $297035.0 (2025), against an average of $310186.2.
• Across the five-year window, Convertible Debt jumped 210.62% in 2025 and surged 209.4% in 2026, its largest moves.
• Quantum Biopharma's Convertible Debt stood at $152113.0 in 2024, then surged by 210.62% to $472497.0 in 2025, then climbed by 2.76% to $485517.0 in 2026.
• The last three Convertible Debt figures came in at $485517.0 (Q1 2026), $472497.0 (Q4 2025), and $429995.0 (Q3 2025), per Business Quant data.